Clinical TrialMay 21, 2026, 08:02 AM
Avalyn Pharma to Present 4-Year AP01 Data at EULAR 2026
AI Summary
Avalyn Pharma Inc. announced an upcoming poster presentation at the European Alliance of Associations for Rheumatology (EULAR) 2026, taking place from June 3-6 in London. The presentation will feature updated findings from the ATLAS open-label extension trial, highlighting the long-term tolerability profile of AP01 (inhaled pirfenidone) in patients with progressive pulmonary fibrosis, with data extending up to four years of treatment. This supports the potential for AP01 to preserve lung function while improving tolerability compared to oral pirfenidone.
Key Highlights
- Avalyn Pharma to present at EULAR 2026, June 3-6, in London.
- Presentation details updated findings from ATLAS open-label extension trial.
- Highlights long-term tolerability profile of AP01 (inhaled pirfenidone).
- Data covers up to four years of treatment for progressive pulmonary fibrosis.
- Presentation title: "Nebulized pirfenidone (AP01) for progressive pulmonary fibrosis..."
- Poster ID: POS1150, Session: Poster View VIII, Saturday, June 6, 10:15 BST.
Price Impact
More from AVLN